Rheumatologists’ Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s Saphnelo (anifrolumab) for SLE, […]
‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights. The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those not currently on a biologic, […]
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
According to Spherix Global Insights, US rheumatologists are most likely to prefer Bimzelx’s dual IL-17A/F pathway as the most efficacious of all interleukins available in PsA. EXTON, PA., April 16, 2024 – In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA), ankylosing […]
Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira (adalimumab, AbbVie). This yawning gap underscores […]
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks to the surprising resilience of AbbVie’s autoimmune blockbuster. Now, in the face of lackluster Cytelzo sales, Boehringer has decided to prune its ranks in the U.S. and adopt […]
Charting New Paths: Non-TNF’s Evolving in Rheumatoid Arthritis Market
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market share, according to Spherix Global Insights. EXTON, PA., February 23, 2024 — Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer […]
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class, first established by Novartis’ Cosentyx and Eli Lilly’s Taltz, according to Spherix Global Insights. EXTON, PA., January 22, 2024 — Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment […]
Lupus drug market growing as physicians adopt newer options — and look for more, research finds
With three relatively new drugs, plus a busy pipeline in both systemic lupus erythematosus (SLE) and lupus nephritis (LN), the lupus market has been taking off. The LN arena is especially busy now with two competitors gaining steam, but SLE is also on physicians’ minds with the potential for CAR-T cell therapy treatment on the […]
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
Lupus patients desire more targeted information on specific treatments available, underscoring an opportunity for the pharmaceutical industry to play a more pivotal role in patient education. [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients, delving into their personal experiences navigating the complex landscape of […]
Greater use of Benlysta, Saphnelo seen in US, EU to treat lupus
In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for autoimmune diseases is tied to serious side effects — among people with moderate to severe lupus. To that end, healthcare professionals are increasingly prescribing biological therapies like Benlysta (belimumab) and Saphnelo (anifrolumab). Those are the main findings of two […]
